Screener
Polaryx Therapeutics, Inc. PLYX Income Statement
| Q1 '26 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | ||
|---|---|---|---|---|---|---|
| $679K-85.6% | $4.72M+571% | $702.75K— | $702.75K— | $702.75K— | ||
| $1.28M+281% | $336K-12.8% | $385.25K— | $385.25K— | $385.25K— | ||
| $1.96M-61.2% | $5.05M+364% | $1.09M— | $1.09M— | $1.09M— | ||
| -$1.96M+61.2% | -$5.05M-364% | -$1.09M— | -$1.09M— | -$1.09M— | ||
| -$2.54M+49.6% | -$5.05M+33.4% | -$7.59M— | -$7.59M— | -$7.59M— | ||
| -$0.05+54.5% | -$0.11+50.6% | -$0.22— | -$0.22— | -$0.22— |
FAQ
- Is Polaryx Therapeutics, Inc. profitable?
- Polaryx Therapeutics, Inc. is not currently profitable: it reported a net loss of $22.8M over the trailing twelve months.
- What is Polaryx Therapeutics, Inc.'s earnings per share?
- Polaryx Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.60.
- Where does Polaryx Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Polaryx Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.